Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

European Neurology, published by KARGER, is a distinguished journal in the field of neurology, catering to both clinical and neuroscience specialties. Since its inception in 1897 and continuing through 2024, the journal has been a vital platform for disseminating significant research findings and insights in neurology. With an ISSN of 0014-3022 and E-ISSN of 1421-9913, it ranks in the Q3 quartile in both clinical neurology and general neurology categories, reflecting its commitment to scholarly excellence while holding the 175th rank in clinical medicine and the 93rd in neuroscience, according to Scopus metrics. European Neurology facilitates a deeper understanding of neurological disorders and treatments, appealing to a diverse readership that includes researchers, clinicians, and students alike. Despite not currently offering open access, the journal’s rigorous peer-review process ensures that only high-quality research reaches its audience, making it an essential resource for those looking to stay informed in the rapidly evolving field of neurology.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, published by the esteemed BMJ PUBLISHING GROUP, is a leading journal that covers pivotal research in the fields of neurology, neurosurgery, and psychiatry. With an impressive impact factor and consistently recognized as a Q1 journal in its respective categories—including Clinical Neurology, Psychiatry and Mental Health, and Surgery—this publication ranks in the top percentiles on Scopus, showcasing its influence in the medical community. Since its inception in 1920, the journal has been committed to delivering high-quality, peer-reviewed content to researchers, clinicians, and students alike, maintaining an exceptional reputation attributed to its rigorous selection process and the depth of its contributions. Access to the journal's articles fosters a comprehensive understanding of progressive research and clinical practices, solidifying its significance for professionals aiming to navigate the complexities of neurological and psychiatric disorders. As a vital resource based in the United Kingdom, the journal continues to propel innovation and knowledge sharing in the ever-evolving landscape of neurohealth.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

Current Neurology and Neuroscience Reports, published by Springer, is a leading peer-reviewed journal dedicated to advancing the field of neurology and neuroscience. With a notable impact factor and a reputable standing in the academic community, as evidenced by its Q1 rankings in both Neurology (Clinical) and Neuroscience (Miscellaneous) for 2023, this journal is ranked #49 out of 400 in clinical neurology and #21 out of 113 in general neuroscience, placing it in the 87th and 81st percentiles respectively.

Since its inception in 2001, it has provided a platform for groundbreaking research, comprehensive reviews, and critical insights into contemporary issues affecting the nervous system. Aimed at researchers, clinicians, and students alike, Current Neurology and Neuroscience Reports fosters interdisciplinary dialogue and knowledge exchange, addressing a broad spectrum of topics from clinical neurology to theoretical neuroscience. By publishing high-quality research, the journal not only contributes to the scientific community but also aims to enhance patient care and inform clinical practices. As a vital resource in neurological research, it invites contributions from a diverse range of studies to expand understanding in this ever-evolving field.

NEUROEPIDEMIOLOGY, published by KARGER, stands as a leading journal in the fields of epidemiology and neurology, with a remarkable impact reflected in its Q1 ranking in both categories for 2023. Since its inception in 1982, the journal has been pivotal in advancing our understanding of neurological disorders through a rigorous scientific lens, making significant contributions to both clinical practice and public health policies. Based in Switzerland, it attracts a global readership of researchers, healthcare professionals, and students committed to leveraging epidemiological insights to combat neurological ailments. While the journal is not open access, its valuable content—covering the full spectrum of neurological disorders, their epidemiology, and related health implications—remains accessible via institutional subscriptions. With a consistent publication schedule leading up to 2024, NEUROEPIDEMIOLOGY continues to elevate the standards of research and discussion within these dynamic fields.

Canadian Journal of Neurological Sciences, published by Cambridge University Press, stands as a reputable source of knowledge in the field of neurology, dedicated to advancing research and clinical practice. With an ISSN of 0317-1671 and an E-ISSN of 2057-0155, this journal has been a cornerstone for the exchange of ideas since its inception in 1974 and will continue to cater to the academic community until 2024. Recognized in the top quartile (Q2) in various categories including Medicine (miscellaneous) and Neurology (clinical), its articles engage a broad audience, ranging from established researchers to students seeking to deepen their understanding of neurological sciences. Although the journal is not an open-access publication, it provides vital insights and research findings that contribute significantly to its fields. With a Scopus rank of #183 in clinical neurology and a percentile ranking that reflects its commendable standing, the Canadian Journal of Neurological Sciences is indispensable for those committed to the exploration and treatment of neurological disorders.

Neurology and Therapy, published by SPRINGER LONDON LTD, stands as a pivotal platform for researchers and practitioners in the field of neurology and its therapeutic applications. This Open Access journal, active since 2012, facilitates the dissemination of innovative studies and cutting-edge findings aimed at improving neurological health. With an impressive ranking in the 2023 Scopus Rankings, where it holds a Q2 category in Neurology and a Q1 category in Clinical Neurology, it underscores its prominence in advancing neurological research. The journal's intriguing scope encompasses a wide-ranging exploration of neurological disorders, treatment methodologies, and healthcare strategies, making it a valuable resource for those vested in enhancing patient outcomes. With an appealing average impact factor, readers are encouraged to dive into the latest advancements and engage with the scholarly discussions that are shaping the future of neurology.

Current Treatment Options in Neurology, published by CURRENT MEDICINE GROUP, is a pivotal journal in the field of clinical neurology, dedicated to enhancing the understanding and management of neurological disorders. With a print ISSN of 1092-8480 and an E-ISSN of 1534-3138, this journal serves as a vital resource for clinicians, researchers, and students alike, providing evidence-based insights and treatment strategies from its continuous publication since its inception in 1999. It currently holds a respectable rank in the Q3 quartile, reflecting its competitive standing in the Scopus rankings for clinical neurology, placing it at the 51st percentile. Although not classified as Open Access, the journal continues to provide valuable contributions that inform clinical practices and improve patient outcomes in neurological care. With its comprehensive reviews and clinical focus, Current Treatment Options in Neurology remains an essential platform for disseminating the latest advancements in treatment methodologies and therapeutic options, solidifying its importance in the ever-evolving landscape of neurology.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.